论文部分内容阅读
目的探讨黄芪联合丹参注射液在胃癌患者化疗期间的应用意义及疗效分析。方法将130例胃癌化疗患者随机分为对照组65例(常规采用FOL-FOX方案进行化疗);观察组65例(FOL-FOX方案基础上加用黄芪联合丹参注射),对照两组治疗前后白细胞(WBC)、癌胚抗原(CEA)、体重水平变化及治疗期间两组患者化疗毒性反应度。结果两组患者治疗前白细胞(WBC)、癌胚抗原(CEA)、体重比较(t=3.21、3.44、3.45,P>0.05,无显著性差异);治疗后白细胞(WBC)、癌胚抗原(CEA)、体重水平比较(t=5.66、6.23、6.77,P<0.05,具有显著性差异);治疗期间两组患者化疗毒性反应度比较(t=4.31、4.56、6.11、5.33、5.43,P<0.05,具有显著性差异)。结论黄芪联合丹参注射液应用于胃癌患者化疗期间可以减少患者化疗毒性反应,增加白细胞水平,具有增效减副作用。
Objective To investigate the clinical significance and therapeutic effect of Astragalus combined with Danshen injection during chemotherapy in patients with gastric cancer. Methods One hundred and thirty patients with gastric cancer were randomly divided into control group (n = 65) treated with FOL-FOX regimen (routinely treated with FOL-FOX regimen) and observation group (n = 65) treated with FOL-FOX plus astragalus plus salvia miltiorrhiza. (WBC), carcinoembryonic antigen (CEA), body weight, and response to chemotherapy in both groups during treatment. Results There was no significant difference in WBC, CEA before and after treatment between two groups (t = 3.21, 3.44, 3.45, P> 0.05). After treatment, WBC, CEA CEA) and body weight (t = 5.66,6.23,6.77, P <0.05, significant difference). The degree of chemotherapy toxicity in the two groups was significantly higher than that in the control group (t = 4.31,4.56,6.11,5.33,5.43, P < 0.05, with significant difference). Conclusion Astragalus combined with Salvia injection applied to gastric cancer patients during chemotherapy can reduce chemotherapy toxicity in patients with increased leukocyte levels with synergistic side effects.